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OBJECTIVES This study was designed to determine adherence to outpatient beta-blocker therapy following
acute myocardial infarction (AMI).
BACKGROUND The importance of beta-blocker therapy after AMI is widely recognized. Outpatient
adherence with this recommendation, however, is not well described.
METHODS Data on 846 patients surviving AMI were studied. Factors associated with filling a
beta-blocker prescription within 30 days postdischarge and the proportion of patients who
were or were not discharged on beta-blockers who filled prescriptions for them by 30, 180,
and 365 days post-AMI discharge were assessed.
RESULTS Patients with a discharge order for beta-blocker therapy were more likely to fill a prescription
in the first 30 days postdischarge (hazard ratio [HR] 15.82, 95% confidence interval [CI],
10.75 to 23.26). Patients older than age 75 years were less likely than those age 65 years to
fill a prescription (HR 0.63, 95% CI 0.42 to 0.93). Gender, race, and being an ideal candidate
did not affect beta-blocker use. Among patients who were discharged on beta-blockers, 85%
of survivors had filled a prescription by 30 days postdischarge, and 63% and 61% were current
users at 180 and 365 days, respectively. In contrast, only 8% of those patients with no
discharge order for beta-blockers had filled such a prescription by 30 days, and 13% and 12%
of patients were current users at 180 and 365 days, respectively.
CONCLUSIONS Patients not discharged on beta-blockers are unlikely to be started on them as outpatients. For
patients who are discharged on beta-blockers after AMI, there is a significant decline in use
after discharge. Quality improvement efforts need to be focused on improving discharge
planning and to continue these efforts after discharge. (J Am Coll Cardiol 2002;40:
1589–95) © 2002 by the American College of Cardiology Foundation
Several clinical trials have convincingly demonstrated the
secondary prevention benefits of beta-blocker therapy after
acute myocardial infarction (AMI) (1,2). On the basis of
these results, the American College of Cardiology (ACC)
and American Heart Association (AHA) guidelines for the
management of AMI recommend routine beta-blocker
therapy for all patients without a contraindication (3).
Despite this, use of these drugs after AMI remains subop-
timal (4). As a result, patients who are not discharged on
beta-blockers have a higher risk of readmissions and mor-
tality (5).
Nearly all studies on this issue have defined beta-blocker
use from discharge orders (4,6). However, patients may fail
to fill prescriptions for discharge medications (7). Further-
more, patients who initially use these medications may later
discontinue their use, either because of intolerance or
noncompliance with recommended care, even though in-
definite use of beta-blockers post-AMI is recommended (3).
Thus, quality improvement efforts restricted to hospitals
may not achieve their promised effectiveness.
In this study, we sought to assess the outpatient utiliza-
tion of beta-blocker therapy during the first year postdis-
charge after AMI. We also assessed the new use of beta-
blockers for eligible patients who were not discharged on
them after AMI. We identified a population-based cohort
of Medicare beneficiaries, discharged alive after an AMI.
The study cohort was that subset of patients who were also
enrolled in the Tennessee Medicaid program at discharge
and, thus, eligible to receive pharmacy benefits, which
enabled us to determine their use of beta-blockers in the
year following discharge.
METHODS
Sources of data. MEDICARE DATA. The original Coopera-
tive Cardiovascular Project collected information on all
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nongovernment AMI hospital discharges over eight-month
periods between 1994 and 1995 that were billed for Medi-
care payment. As an extension of this project, the Tennessee
Quality Improvement Organization used the same data
collection instrument to abstract data on all AMIs in the
state in defined time periods after quality improvement
interventions were implemented. The time frame for data
collection varied, but included at least eight months; because
collection was not started until interventions were in place,
collection periods were staggered between July 1996 and
December 1999.
Medicaid data. The study was conducted among enrollees
of the Tennessee Medicaid program. Medicaid computer-
ized files permitted linkage to the Tennessee Quality Im-
provement Organization data and identification of prescrip-
tions filled for beta-blockers. Medicaid files included the
enrollment file, a registry of all enrollees linked with death
certificates; the pharmacy file, consisting of records of pre-
scriptions filled at the pharmacy; the inpatient file, with the
records of hospitalizations; the outpatient file, with encoun-
ter records for emergency room, hospital outpatient depart-
ment, and physician visits for Medicaid enrollees; and the
nursing home file. Automated pharmacy records are an
excellent source of medication data because these records are
not subject to information bias and have concordance of
better than 90% with patient self-reports of medication use
(8,9).
Study population. A total of 5,358 confirmed AMI hos-
pital discharges were abstracted by the Tennessee Quality
Improvement Organization during the study period. These
included 1,412 (26%) discharges on 1,326 patients enrolled
in Medicaid at discharge. The first hospitalization in which
the patient was discharged to the community was chosen for
this analysis. We excluded 193 (14%) patients who died
during hospitalization and 151 (11%) who were transferred
to another hospital. Although all enrollees in Medicaid have
access to prescription drugs through the program, some may
choose to use other sources of prescription medications
(such as Veterans Administration hospitals); others may be
retroactively enrolled in Medicaid and obtain initial post-
discharge medications through other means. To ensure that
all study subjects were able to fill a prescription through the
Medicaid program, the analysis was restricted to 846 of the
remaining 982 (86%) patients who filled at least one
prescription in the year before discharge or in the first 30
days postdischarge. Of the 846 persons in the study cohort,
788, 681, and 620 subjects were alive and enrolled in
Medicaid at 30, 180, and 365 days post-AMI discharge,
respectively.
Human subjects. This study was approved by Vanderbilt
University and the state of Tennessee Institutional Review
Boards, and reviewed and approved by the Centers for
Medicare and Medicaid Services and by the Tennessee
Medicaid program. Although personal identifiers were used
for data linkage, all analysis files were devoid of identifiers
and were not able to be linked back to data with identifying
information.
Study definitions. We used the same definition of AMI as
was used in the Cooperative Cardiovascular Project (10).
Patients were classified as ideal candidates for beta-blockers
if they had none of the following: heart rate 50 beats/min
and not already on beta-blockers, shock, systolic blood
pressure 100 mm Hg, high-grade atrioventricular block,
asthma, chronic obstructive pulmonary disease, depression,
dementia, left ventricular ejection fraction (LVEF) 35%
or not measured, pulmonary edema, and diabetes mellitus
with insulin therapy. Because the benefit for beta-blocker
therapy post-AMI is limited in patients with very low
cardiac risk, the following patients were also excluded from
the ideal group: no angina 24 h after arrival with no
history of previous AMI, LVEF 50%, no atrial or ven-
tricular arrhythmias, and no ischemia when a stress test was
performed. All patients discharged alive and not classified as
“ideal” candidates were considered “eligible/not ideal” for
beta-blocker therapy.
Clinical data. Clinical data abstracted were the same as the
Cooperative Cardiovascular Project and included demo-
graphics, clinical evaluation and laboratory values, comor-
bidities, procedures, medications, complications, and hos-
pital outcomes. Details of the data collection and definitions
for the Cooperative Cardiovascular Project have been de-
scribed previously (10).
For assessing whether beta-blockers were prescribed at
discharge or not, the abstractors reviewed the chart com-
prehensively, including clinical notes (both physician and
nursing), physician orders, pharmacy sheets, and discharge
summaries. The abstractors were provided with a list of both
generic and trade names of all available beta-blockers.
Outcome. The outcomes studied were the proportion of
study patients who filled a prescription for a beta-blocker
within 30 days after hospital discharge post-AMI, and the
proportion who had a current prescription (filled in the prior
30 days) at 180 and 365 days postdischarge. Prescriptions in
Medicaid are usually for 30 days and may not exceed this
length.
Statistical analysis. Descriptive analyses were performed
and the data were tabulated as means or frequencies.
Proportional hazards regression was used to estimate ad-
justed hazard ratios (HR) and 95% confidence intervals (CI)
assessing patient characteristics related to the time to filling
a beta-blocker prescription within the first 30 days postdis-
charge. Patient characteristics included age (65, 65 to 74,
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
AMI  acute myocardial infarction
CI  confidence intervals
HR  hazard ratio
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75 years), gender (male/female), race (white/black/other),
being an ideal candidate (eligible/not ideal vs. ideal), and
discharge status (discharged on beta-blocker, yes/no). Sim-
ilarly, logistic regression was used to calculate adjusted odds
ratios and 95% CI for the relationship of beta blocker status
at 30, 180, and 365 days to patient characteristics, stratified
by beta-blocker discharge status. Odds ratios were con-
verted to relative risks (RRs) using the method described by
Zhang and Yu (11). Regression diagnostics were performed
to assess the appropriateness of the proportional hazards
and logistic regression models. Data were analyzed using
SAS Version 8 (SAS Institute, Cary, North Carolina).
RESULTS
Patient characteristics. The mean age of the study popu-
lation was 70  13 years. Of the patients, 17% were
considered ideal candidates for beta-blocker therapy, and
46% were discharged on beta-blockers (Table 1). There
were no significant differences in the demographic charac-
teristics among the cohorts studied at 30, 180, and 365 days
post-AMI.
Overall beta-blocker use after discharge. Daily outpatient
adherence to beta-blocker therapy post-AMI is depicted in
Figure 1. Among patients with a documented discharge
prescription for beta-blockers, approximately 80% were
using beta-blockers during the first 30 days as measured by
prescriptions filled. There was a sharp decline around 30
days, which represents gaps in prescriptions refilled, fol-
lowed by an increase and then a gradual decrease which
remained at around 60% to 65% from approximately 90
through 365 days. Among patients without a discharge
prescription for beta-blockers, approximately 7% to 10%
were using beta-blockers during the first 30 days; this figure
plateaued at around 15% by day 180.
Beta-blocker use according to patient characteristics.
Table 1 describes the likelihood of filling a beta-blocker
prescription within 30 days after discharge according to
patient characteristics. A discharge prescription for beta-
blockers was the strongest predictor of filling a prescription
Table 1. Patient Characteristics Associated With Time to First











65 244 (29) 1.0
65–74 287 (34) 0.86 (0.60–1.23)
 75 315 (37) 0.63 (0.42–0.93)
Race
White 651 (77) 1.0
Black 113 (13) 0.69 (0.44–1.09)
Other 82 (10) 1.06 (0.65–1.75)
Gender
Male 367 (43) 1.0
Female 479 (57) 1.35 (0.97–1.52)
Discharge Status
Eligible/nonideal 699 (83) 1.0
Ideal 147 (17) 1.09 (0.79–1.52)
Discharged on beta-blockers
No 460 (54) 1.0
Yes 386 (46) 15.82 (10.75–23.26)
*Adjusted for other all other variables presented in the Table.
Figure 1. Beta-blocker use after acute myocardial infarction. Use of beta-blockers among patients who were and were not given a prescription for them at
discharge. The adherence is shown from discharge to one year postdischarge and includes patients who were alive at any given time period.
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within 30 days (HR 15.82, 95% CI 10.75 to 23.26). Patients
older than 75 years were significantly less likely to have filled
a beta-blocker prescription post-AMI than those 65 years
(HR 0.63, 95% CI 0.42 to 0.93). Gender, race, and being an
ideal candidate did not affect beta-blocker use.
Beta-blocker use at 30, 180, and 365 days post-AMI
according to whether the patients were discharged on
beta-blockers is shown in Tables 2 and 3. Patients older
than 75 years were significantly less likely to be started on
beta-blockers later if they were not discharged on them (RR
0.37, 95% CI 0.16 to 0.87 for 30 days; RR 0.36, 95% CI
0.16 to 0.78 for 180 days; and RR 0.42, 95% CI 0.17 to 0.94
for 365 days). There were no significant differences in the
new use of beta-blockers from day 30 to either day 180 or
365 in any of the other subgroups. Regression diagnostics
indicated no lack of fit in either the proportional hazards or
logistic regression models.
DISCUSSION
Encouraging use of beta-blockers post-AMI has become a
major quality improvement goal because of the demon-
strated benefit of these drugs in improving survival (1,2). In
this regard, there has been some progress made over the past
decade (10,12). Most of this research, however, is based on
hospital treatment at discharge; issues related to outpatient
compliance have been largely unaddressed. It is also not
clear whether there is a period after discharge when the
chances of decrease in beta-blocker use are substantially
higher as compared with other times, or whether there is a
continued progressive decline in adherence over time. For
patients who are not discharged on beta-blockers after
AMI, there is a possibility that these drugs may be started
as outpatients. Without knowing the proportion of this
group of “new users” of beta-blockers as outpatients, neither
Table 2. Patient Characteristics and Beta-Blocker Adherence Among Patients Who Were Discharged on Beta-Blockers
Patient
Characteristics














Overall age (yrs) 365 309 (85) 330 209 (63) 308 188 (61)
65 126 109 (87) 1.0 119 77 (65) 1.0 114 67 (59) 1.0
65–74 134 114 (85) 0.97 (0.83–1.06) 123 79 (64) 1.02 (0.82–1.19) 116 74 (63) 1.08 (0.84–1.28)
 75 105 86 (82) 0.92 (0.74–1.03) 88 53 (60) 0.96 (0.73–1.17) 78 47 (60) 1.01 (0.74–1.25)
Race
White 284 241 (85) 1.0 253 167 (66) 1.0 236 149 (63) 1.0
Black 47 39 (78) 0.90 (0.70–1.03) 47 25 (53) 0.81 (0.57–1.04) 44 22 (50) 0.78 (0.52–1.03)
Other 34 29 (88) 1.03 (0.82–1.12) 30 17 (57) 0.87 (0.58–1.13) 28 17 (59) 0.92 (0.60–1.19)
Gender
Male 158 133 (84) 1.0 149 98 (66) 1.0 139 85 (61) 1.0
Female 207 176 (85) 1.05 (0.94–1.11) 181 111 (61) 0.96 (0.78–1.12) 169 103 (61) 1.00 (0.79–1.18)
Discharge status
Eligible/nonideal 267 227 (85) 1.0 242 157 (65) 1.0 226 138 (61) 1.0
Ideal 98 82 (83) 0.98 (0.86–1.06) 88 52 (59) 0.93 (0.74–1.10) 82 50 (61) 1.01 (0.80–1.20)
*Adjusted for other all other variables presented in the Table.
CI  confidence interval; RR  relative risk.
Table 3. Patient Characteristics and Beta-Blocker Adherence Among Patients Who Were Not Discharged on Beta-Blockers
Patient
Characteristics














Overall age (yrs) 423 36 (9) 351 46 (13) 312 38 (12)
65 105 13 (12) 1.0 96 18 (19) 1.0 93 15 (16) 1.0
65–74 140 14 (10) 0.77 (0.36–1.55) 123 18 (15) 0.73 (0.38–1.33) 107 14 (13) 0.76 (0.36–1.48)
 75 178 9 (5) 0.37 (0.16–0.87) 132 10 (8) 0.36 (0.16–0.78) 112 9 (8) 0.42 (0.17–0.94)
Race
White 325 29 (9) 1.0 278 39 (14) 1.0 241 29 (12) 1.0
Black 53 4 (8) 0.89 (0.31–2.29) 37 3 (8) 0.54 (0.16–1.56) 36 4 (11) 0.89 (0.32–2.25)
Other 45 3 (7) 0.68 (0.20–2.08) 36 4 (11) 0.69 (0.24–1.75) 35 5 (14) 1.06 (0.41–2.46)
Gender
Male 175 14 (8) 1.0 151 18 (12) 1.0 130 13 (10) 1.0
Female 248 22 (9) 1.46 (0.75–2.69) 200 28 (14) 1.36 (0.75–2.30) 182 25 (14) 1.62 (0.84–2.90)
Discharge status
Eligible/nonideal 383 33 (9) 1.0 316 43 (14) 1.0 279 33 (12) 1.0
Ideal 40 3 (8) 0.82 (0.25–2.41) 35 3 (9) 0.59 (0.18–1.69) 33 5 (15) 1.26 (0.49–2.79)
*Adjusted for other all other variables presented in the Table.
CI  confidence interval; RR  relative risk.
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the true epidemiologic significance of beta-blocker under-
utilization can be properly appreciated, nor can appropriate
quality improvement strategies be implemented.
Our study demonstrates a significant decline in the use of
beta-blockers after AMI discharge from the hospital. Over-
all, only 46% of the patients were discharged on beta-
blockers. During the first 30 days after discharge, another
15% of these patients had not filled a beta-blocker prescrip-
tion, and by 180 days, a total of 37% of the patients
discharged on beta-blockers did not have a current prescrip-
tion. We did not find a significant further deterioration in
adherence to these drugs from 180 days to 1 year post-AMI.
Even among those patients classified as ideal for beta-
blocker therapy but not discharged on them, the rate of new
outpatient prescription was very low. These findings
strongly suggest that further quality improvement initiatives
need to address drug compliance in the outpatient arena,
especially considering that similar results have been shown
for lack of adherence with lipid-lowering therapy (13).
Benefit from beta-blocker therapy post-AMI has been
demonstrated in multiple subgroups of patients. These
include patients at high risk for not receiving beta-blockers
(6), those who have undergone coronary revascularization
after AMI (14), those who are diabetic (15), and those with
a history of chronic obstructive pulmonary disease or asthma
(16). Despite this, our data are consistent with earlier
reports that beta-blockers at discharge are significantly
underused. Further decline in the use of these drugs in the
outpatient arena leaves only a minority of patients who
actually take these drugs long-term.
Two prior studies have addressed the outpatient use of
beta-blockers post AMI, but did not have information on
whether these drugs had actually been prescribed at dis-
charge. Soumerai et al. (5) showed that only 21% of the
subjects received one or more prescriptions for beta-blockers
within 90 days post-AMI discharge. Patients who filled a
prescription for beta-blockers as outpatients had a signifi-
cantly lower risk of mortality and readmission at two years
after discharge (5). Another study assessed the proportion of
post-AMI patients using beta-blockers within the first 90
days after discharge and reported a significant increase from
39.6% in 1994 to 58.6% in 1997 (12). Although there was
a definite trend towards improvement, the absolute numbers
may be misleading because active prescription refilling for
any medication within the same 90-day period post-AMI
was an inclusion criterion for the study. Finally, in patients
who have recurrent AMI, the proportion of patients receiv-
ing beta-blockers has been shown to be 50% (17).
Our study shows that the best predictor of patients
receiving beta-blockers at 30 days post-AMI was discharge
prescription of these drugs. This underscores the impor-
tance of careful discharge planning. It is possible that the
patients discharged on beta-blockers were already on them
during the hospital stay and constituted a select group of
patients tolerant to these medications. However, both pa-
tients and the family members are likely to be responsive to
educational opportunity regarding the importance of sec-
ondary prevention measures post-AMI, and may be more
motivated to comply with the recommendations given
during the acute phase. Moreover, physicians may be more
likely to continue a prescription on an outpatient basis as
compared to remembering and initiating a new treatment.
There has been some improvement in the discharge
prescription rate of beta-blockers over time (10,12). How-
ever, recent data collected from 1997 to 1999 on Medicare
beneficiaries still show substantial opportunities for im-
provement across states in beta-blocker prescription at
discharge (18). Increasing compliance with recommended
medicines at hospital discharge has been shown to improve
long-term outcomes in patients post-AMI (19). Because of
such findings, both the AHA and ACC have recently
initiated quality improvement projects to improve compli-
ance with secondary prevention recommendations at dis-
charge after AMI (20,21). These are complementary to the
efforts by the Centers for Medicare and Medicaid Services
and the Joint Commission on Accreditation of Healthcare
Organizations (22,23).
Discharge prescription of medication, however, does not
guarantee continued adherence in the outpatient arena.
Indeed, our data show that 15% of those patients who were
discharged on beta-blockers had not filled a prescription
during the first 30 days after discharge. Although theoret-
ically the patient may have been discharged with a 30-day
supply, this proportion continued to fall to up to 37% by 180
days. Considering that 54% of the eligible patients were not
discharged on beta-blockers, a reduction of another 37% by
six months leaves only a small minority of eligible patients
who actually were taking these medicines for relatively long
periods of time. The estimates we report represent the “best
case” scenario. If we assess the data in our “unrestricted
cohort,” by six months 43% of the patients were not
continuing beta-blocker therapy. These trends can have a
significant clinical and economic impact on the health care
system. It is estimated that if all survivors of first AMI were
treated with beta-blockers for 20 years, this could result in
a saving of $18 million and a gain of 447,000 life-years (24).
Our findings suggest that attempts to improve quality of
care should go beyond discharge planning and include
outpatient efforts. In order to efficiently target these outpa-
tient efforts, it is important to know the temporal trends of
a decline in adherence. Our data suggest that decline is most
likely to occur within the first 180 days. There were no
significant changes noted after six months in either the
overall use or use in any of the subgroups studied. Consid-
ering these results, efforts to improve beta-blocker use after
AMI should continue postdischarge for preferably up to six
months.
In general, there are multiple patient- and physician-
related reasons for lack of compliance with guideline-based
recommendations (25,26). In the case of beta-blockers,
potential adverse effects are considered to be a major reason.
There were multiple potential clinical scenarios in the
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eligible/nonideal patients in our study that may have pre-
vented long-term therapy. However, unlike the early use of
these drugs during admission, our study focuses on dis-
charge use. Therefore, contraindications such as cardiogenic
shock or third-degree heart block are not relevant to our
study. For other relative contraindications such as history of
pulmonary disease, low ejection fraction, and diabetes,
Gottlieb et al. (6) have shown a significant benefit from the
use of these drugs post-AMI in patients with these comor-
bidities. Therefore, to not give beta-blockers to these
patients is inconsistent with literature unless the patients are
truly intolerant. Moreover, many of these conditions are no
longer considered relative contraindications. The recently
published Carvedilol Post-Infarction Survival Control In
Left Ventricular Dysfunction (CAPRICORN) trial showed
that treatment with beta-blockers after an AMI complicated
by left ventricular systolic dysfunction results in a significant
reduction in all-cause and cardiovascular mortality (27).
Restricting the use of these drugs to only ideal patients is
estimated to reduce the epidemiologic impact of beta-
blocker therapy post-AMI by approximately 60% (24).
To further assess this issue, we defined a group of ideal
patients in whom there were no absolute or relative contra-
indications to the use of beta-blockers and who should have
a minimal risk of untoward side effects. Analysis of this
group showed similar trends, with a significant reduction in
adherence at 30 and 180 days. These data suggest that the
root cause for lack of therapy with beta-blockers is likely not
restricted to clinical reasons alone.
Elderly patients were at particularly high risk for not
being discharged on beta-blockers. Existing data suggest
significant benefit from beta-blocker therapy in this group
of patients, and the decision not to treat these patients is
inconsistent with clinical evidence (5,6). Elderly patients are
at particularly high risk for not following outpatient medi-
cation recommendations (28). This group of patients needs
ongoing outpatient efforts to increase compliance with
beta-blockers. Although the elderly were particularly sus-
ceptible to not taking beta-blockers, our study demonstrates
that in every subgroup there was a major gap between the
number of patients eligible for treatment and those actually
treated. Therefore, although the elderly clearly require
special attention, efforts to improve beta-blocker use after
AMI should be targeted to all eligible patients.
Multiple new medications are introduced in the care of
post-AMI patients. Another possibility for the lack of
beta-blocker therapy at discharge may be that physicians
chose to start these drugs during a subsequent outpatient
visit. Therefore, we studied the new use of beta-blockers in
patients who were not discharged on them. Our data show
that only a minority of patients were new users of these
drugs at all three time frames studied. Again, elderly
patients were at the highest risk for not having these
medications initiated. In our study, we could not ascertain
the reason beta-blockers were initiated in these patients
after discharge. Some prescriptions may have been for
treatment of other conditions, such as hypertension, in
which case treatment with these drugs were not targeted
specifically as a secondary preventive measure for AMI, and
other drugs could have been used instead of beta-blockers.
These results underscore the importance of careful discharge
planning.
In order to maximize outcomes after AMI, attempts
should be made to improve upon the current trends.
Multiple interventions directed at patients have been shown
to increase adherence with medications (29). Bradley et al.
(30) recently described the hospital-related factors that were
associated with increased beta-blocker use after AMI. Pro-
spective studies are needed to assess the effectiveness, safety,
and tolerability of these drugs in patients who are at a higher
risk for side effects. Finally, dosages less than those used in
clinical trials have been associated with substantial beta-
blocker benefit after AMI (31). Therefore, patients should
at least be tried on smaller doses if larger doses are not
tolerated.
Study limitations. Our study has several limitations. Be-
cause of the retrospective nature of the study, we do not
have data on tolerability of these medications during hos-
pital stay or after discharge. We cannot ascertain the degree
to which the lack of adherence is related to physician- or
patient-related factors. Our patient population was eligible
for both Medicare and Medicaid benefits. This may repre-
sent a higher risk population and the results may not be
generalizable to other populations. However, patients en-
rolled in Medicaid were a significant proportion of all
Medicare patients with AMI (26%) in our state. In addi-
tion, these patients have prescription pharmacy benefits,
which remove the financial barrier of obtaining their med-
ications.
In conclusion, our study suggests that a significant pro-
portion of patients who are discharged on beta-blockers
after AMI do not fill their prescription as outpatients.
Discharge administration of beta-blockers is the strongest
predictor of continued use. The use of these drugs is less
than optimal in all groups of patients, with elderly patients
at the highest risk. New outpatient prescriptions for those
not discharged on beta-blockers are infrequent. Quality
improvement efforts should focus on improving discharge
planning and should continue for at least one month and
preferably up to six months post-AMI.
Reprint requests and correspondence: Dr. Javed Butler, Cardi-
ology Division, 383-PRB, Vanderbilt University Medical Center,
Nashville, Tennessee 37232. E-mail: javed.butler@vanderbilt.edu.
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